ArticleClinical medicine (London, England)2018
The reversal of anticoagulation in clinical practice .
Article in Clinical medicine (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Discovery of a Reversible Sub-Picomolar Thrombin Inhibitor Using DCC.Angewandte Chemie (International ed. in English) · 2026Article
- Drugs to Prevent and Treat Venous Thromboembolic Disease During Pregnancy.Clinics in perinatology · 2026Review
- An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives.Pharmaceutics · 2026Review
- Asundexian: a systematic review of safety, efficacy, and pharmacological insights in thrombosis.Thrombosis journal · 2025Review
- In the shadow of stability lies ruin: Occult vascular injuries in geriatric pelvic trauma.World journal of clinical cases · 2025Article
- Does the type of oral anticoagulant matter for stroke prevention or bleeding in patients with atrial fibrillation after cardiac surgery? A systematic review and meta-analysis.European heart journal open · 2025Article
- Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment.Biomedicines · 2024Review
- Article
- Effect of prior anticoagulation therapy on outcomes of traumatic brain injury: A systematic review and meta‑analysis.Experimental and therapeutic medicine · 2024Article
- COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a review.Clinical and experimental vaccine research · 2023Review
- The Effect of Warfarin Use on Postoperative Outcomes after Femoral Neck Surgery.Journal of clinical medicine · 2023Article
- Age Stratification in Acute Ischemic Stroke Patients with Heart Failure.Journal of clinical medicine · 2022Article
- Neurosurgical Considerations Regarding Decompressive Craniectomy for Intracerebral Hemorrhage after SARS-CoV-2-Vaccination in Vaccine Induced Thrombotic Thrombocytopenia-VITT.Journal of clinical medicine · 2021Article
- Intravenous Immunoglobulin (IVIG) in Severe Heparin-Induced Thrombocytopenia (HIT) in a Traumatic Brain Injury (TBI) Patient with Cerebral Venous Sinus Thrombosis (CVST).Neurocritical care · 2021Article
- Updated recommendations for the treatment of venous thromboembolism.Blood research · 2021Review
- Viscoelastometry for detecting oral anticoagulants.Thrombosis journal · 2021Article
- Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19.Antibodies (Basel, Switzerland) · 2020Review
- An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants.Advances in hematology · 2020Review
- The past, the present, and the future: reflecting on -medical history as we welcome new leaders.Clinical medicine (London, England) · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Widespread use of anticoagulant drugs for treatment and -prevention of thromboembolic events means it is common to encounter patients requiring reversal of anticoagulation for management of bleeding or invasive procedures. While supportive and general measures apply for patients on all agents, recent diversification in the number of licensed agents makes an understanding of drug-specific reversal strategies essential. Recognising effects upon, and limitations of, laboratory measures of coagulation also plays an important role. An understanding of reversal strategies alone is insufficient to competently care for patients who may require anticoagulation reversal. It is also necessary to reduce the need for reversal through correct prescribing and by employing appropriate periprocedural bridging strategies for elective and semi-elective procedures. Finally, consideration of whether and when to reintroduce an anticoagulant drug following reversal is important not only to balance bleeding and thrombotic risks for individual patients but also for timely management of discharge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.